Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with melanoma progressing on or after a PD-1/L1 blocking antibody

被引：15

作者：

Agarwala, Sanjiv S.

Moschos, Stergios J.

Johnson, Melissa Lynne

Opyrchal, Mateusz

Gabrilovich, Dmitry

Danaher, Patrick

Wang, Fang

Brouwer, Susan

Ordentlich, Peter

Sankoh, Serap

Schmidt, Emmett V.

Meyers, Michael L.

Sullivan, Ryan J.

机构：

[1] St Lukes Hosp, Easton, PA USA

[2] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA

[3] Sarah Cannon Res Inst, Nashville, TN USA

[4] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA

[5] Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA

[6] NanoString Technol Inc, Seattle, WA USA

[7] Syndax Pharmaceut Inc, Waltham, MA USA

[8] Syndax Pharmaceut, Lexington, MA USA

[9] Merck & Co Inc, Kenilworth, NJ USA

[10] Syndax Pharmaceut Inc, New York, NY USA

[11] Massachusetts Gen Hosp, Boston, MA 02114 USA

来源：

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.9530

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9530

引用

页数：1